![Kjell Simonsson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kjell Simonsson
Keine laufenden Positionen mehr
Ursprung des Netzwerks ersten Grades von Kjell Simonsson
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
KI Management AB
![]() KI Management AB Investment ManagersFinance KI Management AB (KIM) is a venture capital investment firm located in Stockholm, on the campus of the Karolinska Institute. They are the investment advisor and manager of the Karolinska Investment Fund KB (KIF). The fund was established in 1999 by the Karolinska Institute and Alecta, a Nordic pension plan. KIM has a partnership agreement with Karolinska Innovations AB, a technology transfer entity of the Karolinska Institute. The Karolinska Institute, founded in 1810, has a medical focus and is responsible for selecting the winner of the Nobel Prize in Physiology or Medicine.
3
| Extinct | Investment Managers | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Kjell Simonsson
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Cellectricon AB
![]() Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Vanderbilt University | College/University | Doctorate Degree | |
Karolinska Institutet | College/University | Doctorate Degree Corporate Officer/Principal | |
FEELGOOD SVENSKA AB (PUBL) | Medical/Nursing Services | Director/Board Member | |
Stockholm School of Economics | College/University | Masters Business Admin | |
International Olympic Committee
![]() International Olympic Committee Movies/EntertainmentConsumer Services International Olympic Committee Organizes Olympic games. The company was founded by Pierre de Coubertin on June 23 1894 and is headquartered in Lausanne, Switzerland. | Movies/Entertainment | Corporate Officer/Principal | |
Karolinska Investment Fund KB
![]() Karolinska Investment Fund KB Investment ManagersFinance Karolinska Investment Fund KB is a healthcare-focused fund based in Stockholm. Targeted portfolio companies are pharmaceutical, biotechnology and medical technology companies located in Sweden. | Investment Managers | Founder | |
Royal Swedish Academy of Engineering Sciences
![]() Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Alfta Rehab Center Holding AB | Director/Board Member | ||
Cobra Biologics Ltd.
![]() Cobra Biologics Ltd. Pharmaceuticals: MajorHealth Technology Cobra Biologics Ltd. engages in development of DNA-based technologies, services and products. It is a international contract development and manufacturing organization (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The company was founded in 1992 and is headquartered in Keele, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Director/Board Member | |
Cobra Biologics Holding AB
![]() Cobra Biologics Holding AB Pharmaceuticals: MajorHealth Technology Cobra Biologics Holding AB manufactures biologics and pharmaceuticals for pre-clinical, clinical, and commercial products. Its services include gene therapies and vaccines, products for testing, process development and scale up of vaccine products, production of sterile drug products, and process development and production, automation, and traceability of programs. The company was founded in 2011 and is headquartered in S?dert?lje, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
SANA AB | Biotechnology | Director/Board Member | |
EuroScience
![]() EuroScience Miscellaneous Commercial ServicesCommercial Services EuroScience engages in the advancement of science. The non-profit company is based in Strasbourg, France. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Arne Ljungqvist Anti-Doping Foundation AB | Director/Board Member | ||
Medkay Konsulting AB | Director/Board Member | ||
Medkay Konsulting HB | Corporate Officer/Principal | ||
Saniona A/S
![]() Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. | Miscellaneous Commercial Services | Director/Board Member | |
Ki Management Partners AB | Director/Board Member |
Statistik
International
Schweden | 18 |
Dänemark | 4 |
Vereinigte Staaten | 2 |
Schweiz | 2 |
Vereinigtes Königreich | 2 |
Sektoral
Health Technology | 7 |
Commercial Services | 6 |
Consumer Services | 5 |
Finance | 3 |
Health Services | 2 |
Operativ
Director/Board Member | 16 |
Corporate Officer/Principal | 5 |
Doctorate Degree | 3 |
Private Equity Investor | 2 |
Independent Dir/Board Member | 2 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Kjell Simonsson
- Unternehmensverbindungen